


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a CCR-2 chemokine receptor-2 antagonist.

2. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



wherein:

X is selected from the group consisting of:

-O-, -NR²⁰-, -S-, -SO-, -SO₂-, and -CR²¹R²²-, -NSO₂R²⁰-,
-NCOR²⁰-, -NCO₂R²⁰-, -CR²¹CO₂R²⁰-, -CR²¹OCOR²⁰-, -CO-,

where R²⁰ is selected from: hydrogen, C₁₋₆ alkyl, benzyl, phenyl,

C₃₋₆ cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C₁₋₃alkyl, C₁₋₃alkoxy, -CO₂H, -CO₂-C₁₋₆ alkyl, and trifluoromethyl,

where R²¹ and R²² are independently selected from: hydrogen, hydroxy,

C₁₋₆ alkyl, -O-C₁₋₆alkyl, benzyl, phenyl, C₃₋₆ cycloalkyl where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C₁₋₃alkyl, C₁₋₃alkoxy, -CO₂H, -CO₂-C₁₋₆ alkyl, and trifluoromethyl;

R¹ is selected from:

-C₁-6alkyl, -C₀-6alkyl-O-C₁-6alkyl-, -C₀-6alkyl-S-C₁-6alkyl-,
-(C₀-6alkyl)-(C₃-7cycloalkyl)-(C₀-6alkyl), hydroxy, -CO₂R²⁰, heterocycle,
-CN, -NR²⁰R²⁶-, -NSO₂R²⁰-, -NCOR²⁰-, -NCO₂R²⁰-, -NCOR²⁰-,
-CR²¹CO₂R²⁰-, -CR²¹OCOR²⁰-, phenyl and pyridyl,

where R²⁶ is selected from: hydrogen, C₁-6 alkyl, benzyl, phenyl, C₃-6 cycloalkyl

where the alkyl, phenyl, benzyl, and cycloalkyl groups can be unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C₁-3alkyl, C₁-3alkoxy, -CO₂H, -CO₂-C₁-6 alkyl, and trifluoromethyl

where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

- (a) halo,
- (b) hydroxy,
- (c) -O-C₁-3alkyl,
- (d) trifluoromethyl,
- (f) C₁-3alkyl,
- (g) -O-C₁-3alkyl,
- (h) -CO₂R²⁰,
- (i) -SO₂R²⁰,
- (j) -NHCOCH₃,
- (k) -NHSO₂CH₃,
- (l) -heterocycle,
- (m) =O,
- (n) -CN,

and where the phenyl and pyridyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, C₁-3alkyl, C₁-3alkoxy and trifluoromethyl;

R² is selected from:

- (a) hydrogen,
- (b) hydroxy,
- (c) halo,
- (d) C₁-3alkyl, where the alkyl is unsubstituted or substituted with 1-6 substituents independently selected from: fluoro, and hydroxy,
- (e) -NR²⁰R²⁶,
- (f) -CO₂R²⁰,

- (g) -CONR²⁰R²⁶,
- (h) -NR²⁰COR²¹,
- (i) -OCONR²⁰R²⁶,
- (j) -NR²⁰CONR²⁰R²⁶,
- (k) -heterocycle,
- (l) -CN,
- (m) -NR²⁰-SO₂-NR²⁰R²⁶,
- (n) -NR²⁰-SO₂-R²⁶,
- (o) -SO₂-NR²⁰R²⁶, and
- (p) =O, where R² is connected to the ring via a double bond;

R³ is oxygen or is absent;

R⁴ is selected from:

- (a) hydrogen,
- (b) C₁₋₆alkyl,
- (c) trifluoromethyl,
- (d) trifluoromethoxy,
- (e) chloro,
- (f) fluoro,
- (g) bromo, and
- (h) phenyl;

R⁵ is selected from:

- (a) C₁₋₆alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro and optionally substituted with hydroxyl,
- (b) -O-C₁₋₆alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (c) -CO-C₁₋₆alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (d) -S-C₁₋₆alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (e) -pyridyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of: halo, trifluoromethyl, C₁₋₄alkyl, and CO₂R²⁰,
- (f) fluoro,

- (g) chloro,
- (h) bromo,
- (i) -C₄₋₆cycloalkyl,
- (j) -O-C₄₋₆cycloalkyl,
- (k) phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of : halo, trifluoromethyl, C₁₋₄alkyl, and CO₂R²⁰,
- (l) -O-phenyl, which may be unsubstituted or substituted with one or more substituents selected from the group consisting of : halo, trifluoromethyl, C₁₋₄alkyl, and CO₂R²⁰,
- (m) -C₃₋₆cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (n) -O-C₃₋₆cycloalkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- (o) -heterocycle,
- (p) -CN, and
- (q) -CO₂R²⁰;

R⁶ is selected from:

- (a) hydrogen,
- (b) C₁₋₆alkyl, and
- (c) trifluoromethyl
- (d) fluoro
- (e) chloro, and
- (f) bromo;

R⁷ is selected from:

- (a) hydrogen, and
- (b) C₁₋₆alkyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, -CO₂H, -CO₂C₁₋₆alkyl, and -O-C₁₋₃alkyl;

R⁸ is selected from:

- (a) hydrogen,
- (b) C₁₋₆alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C₁₋₃alkoxy, hydroxy, -CO₂R²⁰,

- (c) fluoro,
 - (d) $-O-C_{1-3}$ alkyl, where alkyl may be unsubstituted or substituted with 1-3 fluoro, and
 - (e) C_{3-6} cycloalkyl,
 - (f) $-O-C_{3-6}$ cycloalkyl,
 - (g) hydroxy,
 - (h) $-CO_2R^{20}$,
 - (i) $-OCOR^{20}$,
- or R^7 and R^8 may be joined together via a C_{2-4} alkyl or a C_{0-2} alkyl- $O-C_{1-3}$ alkyl chain to form a 5-7 membered ring;

R^9 is selected from:

- (a) hydrogen,
 - (b) C_{1-6} alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C_{1-3} alkoxy, hydroxy, $-CO_2R^{20}$,
 - (c) CO_2R^{20} ,
 - (d) hydroxy, and
 - (e) $-O-C_{1-6}$ alkyl, where alkyl may be unsubstituted or substituted with 1-6 substituents where the substituents are chosen from the group: fluoro, C_{1-3} alkoxy, hydroxy, $-CO_2R^{20}$,
- or R^8 and R^9 may be joined together by a C_{1-4} alkyl chain or a C_{0-3} alkyl- $O-C_{0-3}$ alkyl chain to form a 3-6 membered ring;

R^{10} is selected from:

- (a) hydrogen, and
 - (b) C_{1-6} alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
 - (c) fluoro,
 - (d) $-O-C_{3-6}$ cycloalkyl, and
 - (e) $-O-C_{1-3}$ alkyl, where alkyl may be unsubstituted or substituted with 1-6 fluoro,
- or R^8 and R^{10} may be joined together by a C_{2-3} alkyl chain to form a 5-6 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, $-CO_2R^{20}$, C_{1-3} alkyl, and C_{1-3} alkoxy,

or R^8 and R^{10} may be joined together by a C_{1-2} alkyl-O- C_{1-2} alkyl chain to form a 6-8 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, $-CO_2R^{20}$, C_{1-3} alkyl, and

C_{1-3} alkoxy,


or R^8 and R^{10} may be joined together by a $-O-C_{1-2}$ alkyl-O-chain to form a 6-7 membered ring, where the alkyl are unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, hydroxy, $-CO_2R^{20}$, C_{1-3} alkyl, and C_{1-3} alkoxy;

n is selected from 0, 1 and 2;

the dashed line represents the optional presence of a second bond to form a double bond; and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

3. (previously presented) The method according to claim 2, wherein X is oxygen.

4. (previously presented) A method for treating neuropathic pain comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of the formula:



5. (New) The method of Claim 2, wherein R^1 is isopropyl, R^2 is hydrogen, R^3 is absent, R^4 is hydrogen, R^5 is $-CF_3$, R^6 is hydrogen, R^7 is hydrogen, R^8 is $-OCH_3$, R^9 is hydrogen, X is oxygen, R^{10} is hydrogen, n is 1, and the dashed line is absent, so that the 5-membered ring has no double bonds.